Artivion

Yahoo Finance • last month

Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Idexx Laboratories (IDXX) one of those stocks right now? By taking a look at the stock's year-to-dat... Full story

Yahoo Finance • 3 months ago

Liberty All-Star® Growth Fund, Inc. October 2025 Monthly Update

BOSTON, November 14, 2025--(BUSINESS WIRE)--Below is the October 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, October 2025 Investment Approac... Full story

Yahoo Finance • 3 months ago

Strong Results and Improved Guidance Lifted Artivion (AORT)

Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their upward traject... Full story

Yahoo Finance • 6 months ago

Artivion CEO Mackin sells $528k in shares

Artivion (NASDAQ:AORT) President and CEO James P. Mackin sold 12,500 shares of common stock on August 15, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sale comes as the stock trades near its 52-week h... Full story

Yahoo Finance • 6 months ago

Artivion price target raised to $45 from $32 at Needham

Needham analyst Mike Matson raised the firm’s price target on Artivion (AORT) to $45 from $32 and keeps a Buy rating on the shares. The company’s constant currency revenue growth improved to 14.6% in Q2 from 3.6% in Q1, driven by strong On... Full story

Yahoo Finance • 6 months ago

Artivion raises 2025 revenue guidance to $435M–$443M as On-X and stent grafts drive double-digit growth

Earnings Call Insights: Artivion, Inc. (AORT) Q2 2025 MANAGEMENT VIEW * CEO Pat MacKin reported "strong business momentum continued through the second quarter as we delivered total constant currency revenue growth of over 14% and adjus... Full story

Yahoo Finance • 6 months ago

Artivion stock price target raised to $41 from $35 at Canaccord on strong Q2

Investing.com - Canaccord Genuity raised its price target on Artivion Inc. (NYSE:AORT) to $41.00 from $35.00 on Friday, maintaining a Buy rating following the company’s strong second-quarter performance. The medical device company, with a... Full story

Yahoo Finance • 7 months ago

[Latest] Global Cardiac Tissue Engineering Market Size/Share Worth USD 2,943.92 Million by 2034 at a 16.65% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cardiac Tissue Engineering Market size & share revenue was valued at approximately U... Full story

Yahoo Finance • 7 months ago

Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White... Full story

Yahoo Finance • 7 months ago

Artivion Inc stock reaches 52-week high at 32.38 USD

Artivion Inc’s stock has reached a 52-week high, hitting 32.38 USD, marking a significant milestone for the $1.51 billion market cap company. According to InvestingPro analysis, the stock appears to be trading above its Fair Value, with an... Full story

Yahoo Finance • 8 months ago

Canaccord Genuity initiates Artivion stock with buy rating on aortic repair bets

Canaccord Genuity initiated coverage on Artivion Inc. (NYSE: AORT) with a buy rating and a $35.00 price target on Tuesday. The research firm cited the cardiac surgery company’s strategic investments in aortic arch repair that are "on the v... Full story

Yahoo Finance • 2 years ago

Artivion to Participate in Upcoming Investor Conferences

ATLANTA, Nov. 8, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. (PRNewsfoto/Artivio... Full story